Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00991458 · ClinicalTrials.gov registry record · Phase 2
Study of Cyclosporine in Post-LASIK Patients
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 621
- Enrollment target
NCT00991458: Completed Phase 2 study, sponsored by Allergan.
NCT00991458 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 621 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (367% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00991458, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 621 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of Cyclosporine 0.005% and 0.010% eye drops administered twice daily before and following LASIK surgery.
Primary Outcome
Time to cure is defined as the number of days after laser in situ keratomileusis (LASIK) surgery that the patient has corneal sensitivity (the capability of the cornea to respond to stimulation) ≥ 50 millimeters in all 9 regions of both eyes after LASIK surgery. A patient is considered cured at the first of 2 consecutive visits meeting these criteria. The Inter-Quartile Range presented is actually the 25th Quantile and the 75th Quantile obtained from the Kaplan-Meier Model.
Interventions
- DRUG Cyclosporine 0.010% eye drops
- DRUG Cyclosporine 0.005% eye drops
- DRUG Placebo (Vehicle for Cyclosporine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 621 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
What the finished NCT00991458 record still lists
NCT00991458 is an interventional study that assigns participants to a tested intervention. The registered 621 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (367% higher).
The record links to 0 conditions, and to 3 interventions - of which Cyclosporine 0.010% eye drops is the first listed.
NCT00991458 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00991458 about?
NCT00991458 is a clinical study titled "Study of Cyclosporine in Post-LASIK Patients". This study will evaluate the safety and efficacy of Cyclosporine 0.005% and 0.010% eye drops administered twice daily before and following LASIK surgery.
What is the current status of trial NCT00991458?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 621 participants. The study started on 2009-10. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00991458?
The interventions under investigation include: Cyclosporine 0.010% eye drops (DRUG), Cyclosporine 0.005% eye drops (DRUG), Placebo (Vehicle for Cyclosporine) (DRUG).
Who is sponsoring clinical trial NCT00991458?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00991458's enrollment target sits among peer trials
621 52nd of 2000 higher than 1,949 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06712355 · 621 participants · Phase 3
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- NCT02282969 · 620 participants
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
- NCT02838836 · 620 participants
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
- NCT05538910 · 620 participants · NA
Defining Neurobiological Links Between Substance Use and Mental Illness
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia